期刊
VASCULAR HEALTH AND RISK MANAGEMENT
卷 8, 期 -, 页码 99-113出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/VHRM.S25665
关键词
mobilization; expansion; homing; survival; engraftment
资金
- American Heart Association [AHA0625331B, 09BGIA2050157]
- National Institutes of Health, National Heart, Lung, and Blood Institute [R01HL078701]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078701] Funding Source: NIH RePORTER
Cardiovascular diseases (CVDs) are the leading cause of death worldwide. The use of stem cells to improve recovery of the injured heart after myocardial infarction (MI) is an important emerging therapeutic strategy. However, recent reviews of clinical trials of stem cell therapy for MI and ischemic heart disease recovery report that less than half of the trials found only small improvements in cardiac function. In clinical trials, bone marrow, peripheral blood, or umbilical cord blood cells were used as the source of stem cells delivered by intracoronary infusion. Some trials administered only a stem cell mobilizing agent that recruits endogenous sources of stem cells. Important challenges to improve the effectiveness of stem cell therapy for CVD include: (1) improved identification, recruitment, and expansion of autologous stem cells; (2) identification of mobilizing and homing agents that increase recruitment; and (3) development of strategies to improve stem cell survival and engraftment of both endogenous and exogenous sources of stem cells. This review is an overview of stem cell therapy for CVD and discusses the challenges these three areas present for maximum optimization of the efficacy of stem cell therapy for heart disease, and new strategies in progress.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据